Contrast-induced nephropathy (CIN) is a common complication in patients with impaired kidney function undergoing coronary angiography/angioplasty. We evaluated whether elevated homocysteine (known to be associated with free radical generation and oxidative stress) increases the risk of CIN. Patients (n = 876) with creatinine clearance <60 mL/min undergoing coronary angiography or percutaneous coronary intervention (PCI) were divided into tertiles of homocysteine levels. Contrast-induced nephropathy was defined as ≥0.5 mg/dL or ≥25% creatinine increase 24 to 48 hours post-PCI. A significant relationship was observed between homocysteine levels and the risk of CIN (P = .033), confirmed after correction for baseline confounding factors, adjusted odds ratio, OR (95% confidence interval, [CI]) = 1.68 (1.09-2.59), P = .019. This association was also significant applying the new definition of contrast-induced acute kidney injury (11.9% in group 1, 10.4% in group 2, and 22.8% in group 3; P < .001), adjusted OR (95% CI) = 1.96 (1.3-2.95), P = .001. Future studies are needed to confirm our findings and to define the role of homocysteine in CIN.
NavareseEPKubicaJCastriotaF. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011;7(8):985–994.
2.
De LucaGCassettiEMarinoP. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med. 2009;27(6):712–719.
3.
De LucaGSuryapranataHMarinoP. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis. 2008;50(5):352–382.
4.
De LucaGBellandiFHuberK. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9(12):2361–2370.
5.
BarberUAugusteU. Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013;15(8):386.
6.
JamesMTGaliWATonelliM. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78(8):803–809.
7.
McCulloughPA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419–1428.
8.
MaederMKleinMFehrT. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004;44(9):1763–1771.
9.
MehranRAymongENikolskyE. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004;44(7):1393–1399.
10.
BousheyCJBeresforsSAOmennGSMotulskyAG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049–1057.
11.
StamlerJSOsborneJAJarakiO. Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91(1):308–318.
12.
Van GuldenerCStamFStehouwerCD. Homocysteine metabolism in renal failure. Kidney Int Suppl. 2001;78:S234–S237.
13.
SulimanMEQureshiARBaranyP. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57(4):1727–1735.
14.
De LucaGSuryapranataHGregorioGLangeHChiarielloM. Homocysteine and its effects on in-stent restenosis. Circulation. 2005;112(19):e307–e311.
15.
KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
16.
De LucaGSantagostinoMSeccoGG. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis. 2009;206(1):292–297.
17.
De LucaGSeccoGGSantagostinoM. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis. 2012;22(5):426–433.
18.
De LucaGvan 't HofAWOttervangerJP. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005;26(7):662–666.
19.
Di LorenzoESauroRVarricchioA. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009;158(4):e43–e50.
20.
De LucaGMarinoP. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J. 2007;154(6):1085.e1–e6.
21.
NavareseEPDe LucaGCastriotaF. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011;9(10):1902–1915.
22.
De LucaGDirksenMTSpauldingC. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172(8):611–621.
23.
CapozzoloCPiscioneFDe LucaG. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001;53(4):464–473.
24.
MarenziGCalbiatiAAssanelliE. Chronic kidney disease in acute coronary syndromes. World J Nephrol. 2012;1(5):134–145.
25.
DangasGIakovouINikolskyE. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13–19.
26.
GonzalesDANorsworthyKJKernSJ. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32.
27.
ZoungasSNinomiyaTHuxleyR. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009;151(9):631–638.
28.
FiaccadoriEMaggioreURotelliC. A. Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with non-ionic radiocontrast media. Nephrol Dial Transplant. 2004;19(4):865–869.
KimSJChoiDKoYG. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2011;108(8):1086–1091.
31.
B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;151(2):282–287.
32.
LangeHSuryapranataHDe LucaG. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350(26):2673–2681.
33.
ZappacostaBMastroiacovoPPersichilliS. Homocysteine lowering byfolate-rich diet or pharmacological supplementations in subjects with moderatehyperhomocysteinemia. Nutrients. 2013;5(5):1531–1543.
34.
MikhailidisDPAthyrosVG. Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014;10(1):8–9.
35.
KhanalSAttallahNSmithDE. Statin therapy reduces contrast induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005;118(8):843–849.
36.
AttallahNYassineLMusialJYeeJ, Fisher K The potential role of statins in contrast nephropathy. Clin Nephrol. 2004;62(4):273–278.
37.
WangJHSubeqYMTsaiWCLeeRPHsuBG. Intravenous N-acetylcysteine with salinehydrationimproves renal function and ameliorates plasma totalhomocysteinein patients undergoing cardiac angiography. Ren Fail. 2008;30(5):527–533.
